Evaluation of Cardiovascular Risk Among the Participants of the ESC Congress 2026

Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2026 Participants

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07778784

Acronym

ESC-CVRISK2026

Enrollment

1300

Registered

2026-08-21

Start date

2026-08-28

Completion date

2026-08-31

Last updated

2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risks

Brief summary

The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2026 from 28-31 August 2026 in Munich, Germany. The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.

Interventions

BIOLOGICALCapillary blood draw

Capillary blood draw to assess several cardiovascular risk markers

BEHAVIORALQuestionnaire and Physical Exam

Waist circumference and blood pressure measurements

BIOLOGICALUrine sample

Urine sample

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All attendees including healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2026 from 28 to 31 August 2026 * Subjects who declare that they are able to understand and give informed consent in English * Adult subjects (≥ 18 years of age)

Exclusion criteria

* Subjects not willing to provide his/her consent to participate in the study. * Subjects who are not suitable candidates for blood extraction.

Design outcomes

Primary

Measure	Time frame
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline	Baseline
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baseline	Baseline
Level of agreement between self-perceived cardiovascular risk category and objectively assessed cardiovascular risk category based on the SCORE2 or SMART algorithm	Baseline

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026